Thus, clinical trials implementing ICI therapy in cases of SCLC have been pursued and shown modest increases in progression free survival and overall survival, but additional, specific biomarkers such as PD-L1 are needed to focus on patients who will receive the most therapeutic benefit. Here, CD274 is linked to small cell lung carcinoma.